Hyderabad-based biopharmaceutical company Suven Life Sciences has secured product patents in Russia and Australia for two of its new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases. These patents are valid until 2023. "We are very pleased by the issuance of these patents in these countries to Suven for our drug candidates that are being developed for CNS (central nervous system) disorders which targets an $18 billion potential market opportunity globally," Venkat Jasti, chief executive of Suven, stated in a press release. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. They are useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like attention deficient hyperactivity, Alzheimer's disease, Parkinson's disease, schizophrenia and Huntington's disease.
